Bioanalysis of biological samples is a cornerstone of new drug research and development, providing the quantitative data needed to characterize pharmacokinetics, support bioequivalence studies, and demonstrate drug safety and efficacy. Accredited third-party laboratories perform these determinations using validated LC-MS/MS and ligand-binding methods in compliance with ICH M10, OECD GLP, and related international quality standards. This article explains the sample types, testing items, analytical technologies, validation requirements, and typical applications of biological sample determination in modern pharmaceutical development.
Technical Overview
Bioanalysis of biological samples, also referred to as biological matrix sample determination, is the quantitative measurement of drugs and their metabolites in biological fluids and tissues collected from preclinical animal studies and clinical trials. The resulting concentration–time data form the scientific basis for pharmacokinetic (PK) modeling, toxicokinetic (TK) evaluation, bioavailability and bioequivalence (BE) assessment, and dose-selection decisions across all phases of new drug development.
A modern bioanalytical program is governed by internationally recognized quality frameworks. Key reference standards and guidelines include ICH M10 (Bioanalytical Method Validation and Study Sample Analysis), OECD Principles of Good Laboratory Practice (GLP), ISO/IEC 17025 for laboratory competence, and the pharmacopoeial requirements of GB, USP and EP monographs where applicable. Accredited third-party laboratories operating under these frameworks ensure that every reported concentration is traceable, reproducible and legally defensible in regulatory submissions.
The typical workflow covers method development, formal method validation, study sample analysis, incurred sample reanalysis (ISR), and final reporting. Each step is supported by a comprehensive quality system covering calibration standards, quality control (QC) samples, chain-of-custody documentation, and instrument qualification.
Testing Samples
Plasma, Serum and Whole Blood
Plasma (heparinized or EDTA anticoagulated), serum and whole blood are the most common matrices for systemic exposure assessment. Venous blood samples are collected at designed time points, centrifuged under controlled conditions, and stored frozen at approximately −70 °C or below until analysis to preserve analyte integrity.
Urine
Urine collections over defined intervals are used to determine renal clearance, mass balance and cumulative excretion of parent drug and metabolites. Preservatives and refrigerated collection conditions are selected based on the known stability profile of the analyte.
Tissue and Organ Homogenates
Tissue distribution studies in preclinical species require quantitative analysis of liver, kidney, brain, lung, heart, fat and tumor homogenates, providing insight into tissue penetration, target-site exposure and potential accumulation.
Special Matrices
Cerebrospinal fluid (CSF), saliva, synovial fluid, bronchoalveolar lavage fluid, fecal samples and dried blood spots (DBS) are analyzed for central nervous system programs, non-invasive monitoring, and local-delivery or microbiome-related studies.
Testing Items
Biological sample determination typically covers the following categories of analytes and evaluations:
- Parent drug concentration in plasma, serum, blood, urine and tissue matrices
- Active and major metabolites, including stereoisomeric (chiral) analytes
- Prodrugs and their conversion products
- Endogenous biomarkers and surrogate analytes for pharmacodynamic (PD) evaluation
- Free (unbound) versus total drug concentrations via equilibrium dialysis or ultrafiltration
- Anti-drug antibodies (ADA) and neutralizing antibodies for biopharmaceuticals
- Incurred sample reanalysis (ISR) to confirm reproducibility of study data
- Derived PK parameters: Cmax, Tmax, AUC0–t, AUC0–∞, t1/2, CL, Vd and F
Testing Methods
Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
LC-MS/MS is the platform of choice for small molecules and many peptides, offering exceptional selectivity, sensitivity (sub-ng/mL levels), wide linear ranges and high throughput. Triple-quadrupole instruments operated in multiple reaction monitoring (MRM) mode, coupled with UPLC separation, enable robust quantification even in complex matrices.
Ligand-Binding Assays (LBA)
Large molecules such as monoclonal antibodies, therapeutic proteins, oligonucleotides and endogenous biomarkers are quantified by ELISA, electrochemiluminescence (ECL), and other immunoassay formats. These methods require critical reagent characterization and are validated for selectivity, dilutional linearity and parallelism.
Supporting Chromatographic and Spectrometric Techniques
HPLC with UV or fluorescence detection, UPLC, and GC-MS remain valuable for analytes with strong chromophores, volatile derivatives or specific regulatory expectations. Chiral LC methods are applied for enantiomeric separation when stereospecific pharmacokinetics must be characterized.
Sample Preparation Techniques
Matrix cleanup and concentration steps include protein precipitation (PPT), liquid–liquid extraction (LLE), solid-phase extraction (SPE), immunoaffinity capture, and derivatization. Selection depends on analyte physicochemical properties, required sensitivity and throughput targets.
Method Validation Parameters
Following ICH M10, formal validation demonstrates:
- Selectivity and specificity across at least six independent matrix lots, including hemolyzed and lipemic plasma
- Calibration curve linearity over the intended quantitative range
- Accuracy and precision (intra- and inter-run) within ±15% (±20% at the LLOQ)
- Recovery and matrix effect (ion suppression or enhancement)
- Stability: bench-top, freeze–thaw, long-term frozen, processed-sample and stock-solution stability
- Dilution integrity for samples above the upper limit of quantification
- Carryover evaluation and run acceptance criteria for QC samples
Applications
- Preclinical pharmacokinetics and toxicokinetics supporting IND-enabling packages
- Single- and multiple-ascending-dose (SAD/MAD) Phase I studies, including food-effect and drug–drug interaction assessments
- Bioequivalence and bioavailability studies for generic and 505(b)(2) development
- Population PK and exposure–response analysis in Phase II/III trials
- Special-population studies in renal or hepatic impairment, pediatric and geriatric subjects
- Therapeutic drug monitoring (TDM) and translational biomarker support
- Transporter and metabolite-safety (MIST) evaluations comparing human and animal metabolite profiles
FAQ
What standards govern bioanalysis of biological samples?
Method validation and sample analysis are performed in accordance with ICH M10, OECD GLP principles for nonclinical studies, ISO/IEC 17025 quality requirements, and applicable national pharmacopoeial standards. Clinical bioanalysis additionally follows Good Clinical Laboratory Practice (GCLP) expectations.
How much sample volume is required?
Typical LC-MS/MS assays require 20–100 µL of plasma per analysis, enabling serial bleeding designs in small rodents. Ligand-binding assays generally require 50–200 µL. Minimal-volume and dried blood spot approaches are available for pediatric and fragile-population studies.
What sensitivity can be achieved?
For small molecules, validated lower limits of quantification in the low pg/mL to ng/mL range are routinely achievable by LC-MS/MS. For biologics, immunoassay sensitivity typically reaches sub-ng/mL to low ng/mL levels depending on critical reagent quality.
What is incurred sample reanalysis (ISR)?
ISR is the repeat analysis of a proportion of study samples to verify the reproducibility of the original reported concentrations. Acceptance generally requires at least two-thirds of reanalyzed samples to agree within ±20% (±30% for ligand-binding assays) of the original value.
How long does a bioanalytical project take?
Method development and validation typically require 4–8 weeks depending on matrix complexity, followed by sample analysis schedules aligned with the study protocol. Rush timelines can be accommodated for early-phase clinical programs with prior planning.